Correction: Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma - Top-Institutions - MDSpire

Correction: Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma

  • By

  • Shanshan Xu

  • Feiran Chen

  • Lei Diao

  • Weiyu. Wang

  • Xuemin Wang

  • Qiong Wu

  • Peipei Sun

  • Yating Hao

  • Yuqian Wang

  • Rongjie Ji

  • Yanan Jiang

  • Jun Du

  • Bing Ang

  • Zhigang Zhao

  • Qing Yang

  • April 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Immunotherapy
    • Clinical Trials

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Urologic Oncology
    • Immuno-oncology
    • Translational Research

  • #3

    Tianjin Medical University Cancer Institute and Hospital
    Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

    Key Differentiators

    • Urogenital Cancer
    • Immunotherapy
    • Clinical Research

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urologic Oncology
    • Immunotherapy
    • Clinical Trials

Original Source(s)

Correction: Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma

  • by Shanshan Xu, Feiran Chen, Lei Diao, Weiyu. Wang, Xuemin Wang, Qiong Wu, Peipei Sun, Yating Hao, Yuqian Wang, Rongjie Ji, Yanan Jiang, Jun Du, Bing Ang, Zhigang Zhao, Qing Yang

  • April 30, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort